Page 4 - PaxGenBio Co., Ltd.

TECHNOLIGY
Proprietary patent technology MPCR-ULFA

Multiplex PCR – Universal Lateral Flow Assay
• Convergence of Multiplex Molecular Diagnosis and Rapid diagnostic test Technology
• The proprietary technology of PaxGenBio, which can be combined with the universal probe of the NC membrane
regardless of the sequence of PCR products.
• South Korea, U.S. patent registration, application from seven foreign countries

Gold-Strepto Avidin is combined with Combination of universal region of target
biotin labeled PCR products amplifying amplification PCR product and universal
the genomic target area. probe.

Nanogold also has the advantage of Reaction line is turned to red by
improving the ability to combine with the nanogold
probe by facilitating the physical flow of
PCR products.
Sample Pad Reaction line area

Loading Multiplex- Conjugation Pad Membrane Absorption pad
PCR products Lateral Flow Lateral Flow

Smart Molecular Diagnosis Technology MPCR-ULFA
Existing Major Molecular Diagnostic Product Technology

Nucleic acid Target nucleic Confirmation by Conventional PCR
extraction from a acid amplification electrophoresis Advantage : Affordable price
specimen It is required to
Disadvantage : It takes a lot of labor/time develop low-cost
Thermal cycler molecular
Target Nucleic Acid Amplification Real-time PCR diagnostic products
with maintaining
and Real-Time Verification Advantage : Easy of use
RFU user convenience
Detector Disadvantage : Difficult to do multiplex
Thermal cycler Cycler over 5 plexes with expensive reagents

MPCR-ULFA Target nucleic acid amplification and Convenient on-site confirmation of PCR
(Universal Lateral Flow Assay) confirmation using Lateral Flow Assay results
Use on inexpensive universal kit (membrane)
New molecular diagnosis
technology with low coast and PCR Patent No : 10-1727111 (UPAH Tech.)
product
convenience Thermal cycler loading Kit for Patent No : 10-1795773 (CAO Tech.)
checking
results
▪ Rapid Multiplex Molecular Diagnosis System

MPCR (Multiplex Polymerase Chain Reaction)
• Multiple diagnosis possible
• Simultaneous amplification of various disease-related genes • Securing high productivity and price
competitiveness
ULFA (Universal Lateral Flow Assay array • User convenience increase
• Rapid diagnosis possible
• Results interpretation within 10 to 20 minutes